Singulair (montelukast sodium) (DrugBank: Montelukast)
5 diseases| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 13 | Multiple sclerosis/Neuromyelitis optica | 0 |
| 46 | Malignant rheumatoid arthritis | 0 |
| 85 | Idiopathic interstitial pneumonia | 0 |
| 98 | Eosinophilic gastrointestinal disease | 0 |
| 228 | Bronchiolitis obliterans | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00656058 (ClinicalTrials.gov) | June 17, 2008 | 9/4/2008 | Montelukast to Treat Bronchiolitis Obliterans | Multi-Institutional Prospective Phase II Study of Montelukast for the Treatment of Bronchiolitis Obliterans Following Allogeneic or Autologous Stem Cell Transplantation in Children and Adults | Bronchiolitis Obliterans;Chronic Graft Versus Host Disease;Leukotriene;Montelukast;Stem Cell Transplant | Drug: Singulair (Montelukast Sodium) | National Cancer Institute (NCI) | NULL | Completed | 6 Years | 80 Years | All | 25 | Phase 2 | United States |